According to Zhitong Finance App News, Oriental Biotech (688298.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 464 million yuan, an increase of 15.15%; net profit loss attributable to shareholders of listed companies was 222 million yuan, an increase over the previous year; net profit loss after deducting non-recurring profit and loss was 238 million yuan, an increase over the previous year; and basic earnings per share were 1.16 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.